Camurus Logo

Camurus

ISIN

SE0007692850

Ticker

CAMX

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

Sweden

Year Founded

1991

About Camurus

Company Description

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions.

New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of opioid dependence and chronic pain, rare diseases, oncology and supportive care, which are developed in-house and in collaboration with international pharmaceutical companies.

Headquarters

Ideongatan 1A
22362, Lund
Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 1,044,098,000.00 1,081,897,000.00 1,305,488,000.00
Noncurrent Assets N/A 375,612,000.00 402,595,000.00 390,143,000.00
Fixtures And Fittings N/A 8,805,000.00 9,882,000.00 9,270,000.00
Intangible Assets Under Development N/A 36,597,000.00 33,713,000.00 23,597,000.00
Noncurrent Receivables N/A N/A 0.00 6,997,000.00
Deferred Tax Assets N/A 305,116,000.00 334,153,000.00 324,667,000.00
Current Assets N/A 668,486,000.00 679,302,000.00 915,345,000.00
Inventories N/A 111,349,000.00 107,202,000.00 107,431,000.00
Current Trade Receivables N/A 52,191,000.00 135,994,000.00 196,863,000.00
Other Current Receivables N/A 35,490,000.00 17,887,000.00 21,782,000.00
Cash and cash equivalents 358,744,000.00 461,793,000.00 411,575,000.00 565,539,000.00
Equity And Liabilities N/A 1,044,098,000.00 1,081,897,000.00 1,305,488,000.00
Issued Capital N/A 1,356,000.00 1,371,000.00 1,386,000.00
Retained Earnings N/A -950,999,000.00 -1,039,858,000.00 -980,448,000.00
Additional Paidin Capital N/A 1,797,084,000.00 1,887,395,000.00 1,973,733,000.00
Equity Attributable To Owners Of Parent N/A 847,441,000.00 848,908,000.00 994,671,000.00
Noncurrent Liabilities N/A 20,387,000.00 19,944,000.00 29,175,000.00
Noncurrent Payables On Social Security And Taxes Other Than Income Tax N/A N/A 1,019,000.00 12,532,000.00
Current Liabilities N/A 176,270,000.00 213,045,000.00 281,642,000.00
Trade And Other Current Payables To Trade Suppliers N/A 20,712,000.00 52,857,000.00 85,548,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A 125,561,000.00 151,805,000.00
Current Tax Liabilities Current N/A 2,839,000.00 6,936,000.00 9,018,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 335,997,000.00 600,570,000.00 956,340,000.00
Profit Loss From Operating Activities -205,232,000.00 -110,574,000.00 71,956,000.00
Finance Income 194,000.00 171,000.00 2,695,000.00
Finance Costs 1,541,000.00 1,365,000.00 1,526,000.00
Profit Loss Before Tax -206,579,000.00 -111,768,000.00 73,125,000.00
Income Tax Expense Continuing Operations -39,314,000.00 -21,322,000.00 17,572,000.00
Profit (loss) -167,265,000.00 -90,446,000.00 55,553,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -167,265,000.00 -90,446,000.00 55,553,000.00
Adjustments For Decrease Increase In Inventories N/A -78,257,000.00 4,147,000.00 374,000.00
Adjustments For Decrease Increase In Other Operating Receivables N/A -2,663,000.00 -8,805,000.00 -19,200,000.00
Adjustments For Increase Decrease In Trade Account Payable N/A 3,325,000.00 32,145,000.00 32,118,000.00
Adjustments For Increase Decrease In Other Operating Payables N/A 54,771,000.00 2,993,000.00 27,566,000.00
Adjustments For Depreciation And Amortisation Expense N/A 11,551,000.00 25,204,000.00 52,248,000.00
Adjustments For Sharebased Payments N/A N/A 12,500,000.00 N/A
Interest Paid Classified As Operating Activities N/A 1,541,000.00 1,365,000.00 1,526,000.00
Interest Received Classified As Operating Activities N/A 194,000.00 171,000.00 2,695,000.00
Cash Flows From Used In Operating Activities N/A -238,832,000.00 -143,427,000.00 101,199,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 968,000.00 3,991,000.00 1,905,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 2,358,000.00 952,000.00 -7,287,000.00
Cash Flows From Used In Investing Activities N/A -3,326,000.00 -4,943,000.00 5,382,000.00
Proceeds From Issuing Other Equity Instruments N/A 8,761,000.00 243,000.00 0.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 4,782,000.00 7,142,000.00 7,786,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities N/A N/A 0.00 -7,001,000.00
Cash Flows From Used In Financing Activities N/A 347,852,000.00 98,904,000.00 43,705,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 105,694,000.00 -49,466,000.00 150,286,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -2,645,000.00 -752,000.00 3,678,000.00
Cash and cash equivalents 358,744,000.00 461,793,000.00 411,575,000.00 565,539,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2022 - Q4 Swedish 🇸🇪 Published: 09.05.2023
  • Consolidated Report 2021 - Q4 Swedish 🇸🇪

Insider Trades

Date Trading entity / Person Association Trade type Volume
17.06.2024 Jon Uguzne Garay Alonso Other Other SEK 0.00
14.05.2024 Torsten Malmström Other Sell SEK 844,675.00
10.05.2024 Annette Mattsson Other Sell SEK 550,000.00
15.12.2023 Annette Mattsson Other Other SEK 169,500.00
18.09.2023 Annette Mattsson Other Sell SEK 294,600.00
06.09.2023 Maria Lundqvist Other Other SEK 0.00
23.08.2023 Maria Lundqvist Other Sell SEK 22,610.28
23.08.2023 Maria Lundqvist Other Sell SEK 17,032.86
23.08.2023 Maria Lundqvist Other Other SEK 13,051.50
23.08.2023 Maria Lundqvist Other Sell SEK 2,932.60

Capital Markets Information

ISIN

SE0007692850

LEI

5493003S6Z6VI7WYFQ06

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.